Abstract:Hypoxia or low oxygen concentration in tumor microenvironment has widespread effects ranging from altered angiogenesis and lymphangiogenesis, tumor metabolism, growth, and therapeutic resistance in different cancer types. A large number of these effects are mediated by the transcription factor hypoxia inducible factor 1⍺ (HIF-1⍺) which is activated by hypoxia. HIF1⍺ induces glycolytic genes and reduces mitochondrial respiration rate in hypoxic tumoral regions through modulation of various cells in tumor microenvironment like cancer-associated fibroblasts. Immune evasion driven by HIF-1⍺ further contributes to enhanced survival of cancer cells. By altering drug target expression, metabolic regulation, and oxygen consumption, hypoxia leads to enhanced growth and survival of cancer cells. Tumor cells in hypoxic conditions thus attain aggressive phenotypes and become resistant to chemo- and radio- therapies resulting in higher mortality. While a number of new therapeutic strategies have succeeded in targeting hypoxia, a significant improvement of these needs a more detailed understanding of the various effects and molecular mechanisms regulated by hypoxia and its effects on modulation of the tumor vasculature. This review focuses on the chief hypoxia-driven molecular mechanisms and their impact on therapeutic resistance in tumors that drive an aggressive phenotype. Impact statement Hypoxia contributes to tumor aggressiveness and promotes growth of many solid tumors that are often resistant to conventional therapies. In order to achieve successful therapeutic strategies targeting different cancer types, it is necessary to understand the molecular mechanisms and signaling pathways that are induced by hypoxia. Aberrant tumor vasculature and alterations in cellular metabolism and drug resistance due to hypoxia further confound this problem. This review focuses on the implications of hypoxia in an inflammatory TME and its impact on the signaling and metabolic pathways regulating growth and progression of cancer, along with changes in lymphangiogenic and angiogenic mechanisms. Finally, the overarching role of hypoxia in mediating therapeutic resistance in cancers is discussed.

Role of hypoxia in the tumor microenvironment and targeted therapy

Tumor hypoxia: From basic knowledge to therapeutic implications

Hypoxia Signaling in Cancer: Implications for Therapeutic Interventions

The cellular-centered view of hypoxia tumor microenvironment: Molecular mechanisms and therapeutic interventions

Tumor hypoxia unveiled: insights into microenvironment, detection tools and emerging therapies

Hypoxic tumor microenvironment: Implications for cancer therapy

Role of hypoxia in cancer therapy by regulating the tumor microenvironment

Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy

Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications

The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies

Therapeutic targeting of the hypoxic tumour microenvironment

The role of hypoxic microenvironment in the progress of tumor

Research progress on tumor hypoxia-associative nanomedicine

The regulation of immune checkpoints by the hypoxic tumor microenvironment

Tumorigenesis and Progression As A Consequence of Hypoxic TME：A Prospective View upon Breast Cancer Therapeutic Targets

Molecular responses to hypoxia in tumor cells

Tumor Hypoxia: Impact on Radiation Therapy and Molecular Pathways

Hypoxic tumor microenvironment: Opportunities to develop targeted therapies

Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation

Current Advances in Modulating Tumor Hypoxia for Enhanced Therapeutic Efficacy.

Hypoxia and the Tumor Microenvironment